System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Philippe Saiag is an expert in Dermatology at Hôpital Ambroise-Paré (France). As of October 2026, ScienceLeadR ranks Philippe Saiag in the top 1% of experts worldwide for Skin Neoplasms, Melanoma and Carcinoma. Philippe Saiag has authored 547 publications, the most recent in 2026, and is an investigator in 29 clinical trials, 3 of them ongoing. SLR score: 1,674 (community average: 125). How the SLR is computed.

LeadR Profile

Philippe Saiag Hôpital Ambroise-Paré France
1 674 ScienceLeadR Reputation 1674

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1993 - 2026
Source: PubMed

Hôpital Ambroise-Paré

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 547

Citations

Citations: 17 212 1st author: 46 Last author: 107 Unique author: 6

Main journals

Ann Dermatol Venereol 165
J Clin Oncol 53
Eur J Cancer 40
J Eur Acad Dermatol Venereol 29
Ann Oncol 23

Best Journals

J Clin Oncol 18
Ann Oncol 13
Lancet Oncol 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.
PMID 42667537 — safety, melanoma, nivolumab, therapeutics		Dermatol Ther (Heidelb)20260
The Role of General Practitioners in Actinic Keratosis Management in Europe: A Dermato-Oncologists Initiative.
PMID 42652870 — general practitioners, keratosis, keratosis, actinic, oncologists, dermatologists		J Clin Med20260
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.
PMID 42263355 — radiotherapy, cells, carcinoma, squamous cell, neoplasms, therapeutics, cutaneous squamous cell carcinoma		Eur J Cancer20260
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.
PMID 42248744 — cells, carcinoma, squamous cell, neoplasms, neoplasm metastasis, risk factors, cutaneous squamous cell carcinoma		Eur J Cancer20260
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.
PMID 42025759 — cells, vaccines, progression-free survival, melanoma, neoplasms, drug-related side effects and adverse reactions, cancer vaccines		Ann Oncol Top journal20260

Clinical Studies 29

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7

By phase:

Phase 2 10
Phase 3 10
N/A 6
Phase 1 2
Phase 4 1

By status:

Completed 15
Active not recruiting 7
Unknown 3
Recruiting 2
Not yet recruiting 1
Terminated 1

By type:

Interventional 24
Observational 5

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 0
multicentric5to9 1
multicentricup10 21

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Evaluation of the Efficiency and Economic Impact of LC OCT (Line field Confocal Optical Coherence Tomography) for the Diagnosis and Management of Basal Cell Carcinomas
NCT06271603 — skin, cells, tomography, biopsy, tomography, optical coherence, diagnosis, carcinoma, basal cell, carcinoma		N/ANot yet recruiting2024
Phase II Trial of Neoadjuvant and Adjuvant IO102 IO103 and Pembrolizumab KEYTRUDA in Patients With Resectable Tumors
NCT05280314 — cells, b7-h1 antigen, dioxygenases, carcinoma, squamous cell, melanoma, neoplasms, multiple chronic conditions, squamous cell carcinoma of head and neck, ligands, indoleamine-pyrrole 2,3,-dioxygenase, carcinoma		Phase 2Recruiting2023
Binimetinib Encorafenib Pembrolizumab Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
NCT04074096 — brain neoplasms, research design, radiosurgery, melanoma, brain, neoplasms, tablets, capsules, neoplasm metastasis, wounds and injuries, mutation		Phase 2Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS